by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Novo Nordisk is forging a future beyond the patent expiration for its lucrative molecule semaglutide, which is behind the company’s best-selling drug by some distance, diabetes treatment Ozempic, which sold for DKK 33.7bn (USD 5.2bn) in 2021 alone.
With the goal of securing a post-semaglutide future, Novo Nordisk is searching far and wide – not just for one candidate but for a long list of new drugs to compensate for the enormous gap that will be left once the semaglutide patent runs out.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Biostatistician 
Scientific Writer 
Analytical Coordinator for Analytical Development 
Nordic Medical Affairs Manager 
IRT Manager, Clinical Drug Supply 
Senior Chemical Safety Advisor 
Chemist for Incoming Materials in QC Department 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Project Manager & Scrum Master 
Production Director 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Clinical Trial Manager for development of in vitro diagnostics 
Clinical Trial Manager 
(Senior) Drug Substance Specialist